Inclusion Criteria:  Age ≥18 years; Baseline NIHSS score ≥6; Subject has acute occlusion located in Vertebral artery(VA) / Internal Carotid Artery (ICA) / M1or M2 segment of Middle Cerebral Artery (MCA) / Basilar artery (BA) diagnosed by DSA; Femoral artery puncture is expected to be completed within 24 hours of onset； mRS score≤ 2; Subject or legal representative is able to understand the purpose of study, agrees to comply with protocol requirements and has provided written informed consent.  Exclusion Criteria:  Chronic occlusion in the target area; Epilepsy at the time of stroke； Bleeding from the gastrointestinal or urinary system in the past three weeks； After drug control, systolic blood pressure was greater than 185mmhg and / or diastolic blood pressure was greater than 110mmhg; International Normalized Ratio(INR)>3; Random blood glucose < 2.7mmol/L or > 22.2mmol/L; Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors, - systemic infection, active disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe mental illness); Tortuous lesion / severe stenosis in the starting segment of the carotid artery / Carotid dissection / Arteritis judged by researchers that is not suitable for the procedure; Acute occlusion of bilateral carotid arteries； Intracranial hemorrhage or massive infarction diagnosed by CT or MR; History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast agents; Expected life <12 months; Female subjects who are pregnant or planning to become pregnant or lactate within the study period; Subject has participated in any other drug or medical device clinical trials in 1 month before signing informed consent; Other circumstances judged by researchers that are not suitable for enrollment .